Working… Menu
Trial record 1 of 1 for:    ged-0301-cd-001
Previous Study | Return to List | Next Study

A Randomized, Double-blind, Study to Explore the Effect of GED-0301 in Subjects With Active Crohn's Disease

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT02367183
Recruitment Status : Completed
First Posted : February 20, 2015
Last Update Posted : January 10, 2019
Information provided by (Responsible Party):

Brief Summary:
This study is design to explore the effect of GED-0301 on clinical and endoscopic outcome and to evaluate its safety in subjects with active Crohn's disease.

Condition or disease Intervention/treatment Phase
Crohn Disease Drug: GED-0301 Drug: Placebo Phase 1

  Show Detailed Description

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 64 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Randomized, Double-blind, Multicenter Study to Explore the Effect of GED-0301 on Endoscopic and Clinical Outcomes in Subjects With Active Crohn's Disease.
Actual Study Start Date : April 8, 2015
Actual Primary Completion Date : September 6, 2016
Actual Study Completion Date : December 14, 2017

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Crohn's Disease

Arm Intervention/treatment
Experimental: GED-0301 160mg QD 12 WK
GED-0301 160 mg once daily (QD) for 12 weeks
Drug: GED-0301
Experimental: GED-0301 160 mg QD 8 WK
GED-0301 160 mg QD for 8 weeks followed by 4 weeks of placebo
Drug: GED-0301
Drug: Placebo
Experimental: GED-0301 160 mg QD 4 WK
GED-0301 160 mg QD for 4 weeks followed by 8 weeks of placebo
Drug: GED-0301
Drug: Placebo

Primary Outcome Measures :
  1. Change in SES-CD Score [ Time Frame: Week 12 ]
    The change from baseline in the Simplified Endoscopic Activity Score for Crohn's disease (SES-CD) score at Induction Week 12.

Secondary Outcome Measures :
  1. Proportion of subjects achieving a clinical remission, defined as a CDAI score < 150 at Induction Week 4 [ Time Frame: Week 4 ]
    Clinical remission is defined as a Crohn's Disease Activity Index (CDAI) score < 150

  2. Adverse Event (AE) [ Time Frame: Up to 97 weeks ]
    Assessed by the type, frequency and severity of adverse events, and its relationship to investigational product (IP), discontinuation due to adverse events, and clinically significant changes in vital signs, Electrocardiograms (ECGs), and/or laboratory findings.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Is a male or female who is ≥18 years at the time of signing the Informed Consent Form (ICF).
  2. Understand and voluntarily sign an Informed Consent Form (ICF) prior to conducting any study related assessments/procedures.
  3. Able to adhere to the study visit schedule and other protocol requirements.
  4. Diagnosis of Crohn's Disease (CD) with a duration of at least 3 months prior to screening.
  5. Diagnosis of ileitis, ileocolitis or colitis , as determined by endoscopic, radiographic or any other imaging modality (eg, magnetic resonance imaging [MRI], computed tomography [CT] scan) evaluation performed within 2 years prior to screening. Subjects with colitis restricted to the left colon will not be allowed in the trial.
  6. Active disease, defined as Crohn's Disease Activity Index (CDAI) score ≥ 220 and ≤ 450 (range: 0 to 600) at screening.
  7. Simple Endoscopic Score for Crohn's Disease (SES-CD) score ≥ 7 at screening. Subjects with ileitis only will require Simple Endoscopic Score for Crohn's Disease (SES-CD) ≥ 4
  8. Must have failed or experienced intolerance to at least one of the following:

    aminosalicylates, budesonide, systemic corticosteroids, immunosuppressants (ie, 6 mercaptopurine [6-MP], azathioprine [AZA], or methotraxate [MTX]) or tumor necrosis factor-α tumor necrosis factor-α (TNF-α) blockers (eg, infliximab, adalimumab or certolizumab) .

  9. Subjects receiving oral aminosalicylates may continue their use during the study, provided that dose has been stable for at least 2 weeks prior to screening. The dose of oral aminosalicylates must remain stable through the duration of the study or early termination from the study. If oral aminosalicylates have been recently discontinued, treatment must have been stopped at least 2 weeks prior to screening.
  10. Subjects receiving oral corticosteroids may continue their use during the Induction Phase, provided that the dose (prednisone ≤ 20 mg/day or equivalent, budesonide ≤ 9 mg/day) has been stable for 3 weeks prior to screening. If oral corticosteroids were recently discontinued, discontinuation must have been completed at least 4 weeks prior to screening. Corticosteroid doses should remain stable until the subject is eligible to start corticosteroids tapering.
  11. Subjects receiving immunosuppressants, such as , 6 mercaptopurine (6-MP), azathioprine (AZA), or methotraxate (MTX) may continue their use during the study, provided that treatment was initiated ≥ 12 weeks prior to screening. The dose of immunosuppressants must be at a stable dose for ≥ 8 weeks prior to the Baseline Visit and must remain stable through the duration of the study or early termination from the study. Subjects who discontinued immunosuppressants should have stopped them at least 8 weeks prior to screening.
  12. Must meet the following laboratory criteria:

    1. White blood cell count ≥ 3000/mm3 (≥ 3.0 X 10^9//L) and < 14,000/mm3 (< 14.0 X 10^9/L)
    2. Platelet count ≥ 100,000/mm3 (≥ 100 X 10^9/L)
    3. Serum creatinine ≤ 1.5 mg/dL (≤ 132.6 μmol/L)
    4. Aspartate aminotransferase (AST) / serum glutamic-oxaloacetic transaminase (SGOT) and alanine aminotransferase (ALT) / serum glutamic-pyruvic transaminase (SGPT) ≤ 2 X upper limit of normal (ULN)
    5. Total bilirubin ≤ 2 mg/dL (≤ 34 μmol/L) unless there is a confirmed diagnosis of Gilbert's disease
    6. Hemoglobin ≥ 9 g/dL (≥ 5.6 mmol/L)
    7. Activated partial thromboplastin time (APTT) ≤ 1.5 X ULN
  13. Females of childbearing potential (FCBP) must have a negative pregnancy test at Screening and the Baseline Visit. While on IP and for at least 28 days after the Early Termination Visit or the end-of-study visit (Observation Week 52 or Extension Week 24), FCBP who engage in activity in which conception is possible must use 1 of the approved contraceptive options2 described below: Option 1: Any one of the following highly effective methods: hormonal contraception (for example, birth control pills, injection, implant, transdermal patch, vaginal ring); intrauterine device (IUD); tubal ligation (tying your tubes); or a partner with a vasectomy OR

    Option 2: Any two of the following effective methods: male or female condom PLUS one of the following additional barrier methods:

    1. diaphragm with spermicide;
    2. cervical cap with spermicide; or
    3. contraceptive sponge with spermicide
  14. Male subjects (including those who have had a vasectomy) who engage in activity in which conception is possible must use barrier contraception (male latex condom or nonlatex condom NOT made out of natural [animal] membrane [for example, polyurethane]) while on Investigational Product (IP) and for at least 28 days after the Early Termination Visit or the end-of-study visit (Observation Week 52 or Extension Week 24).

Exclusion Criteria:

  1. Diagnosis of Crohn's colitis restricted to the left colon , ulcerative colitis (UC), indeterminate colitis, ischemic colitis, microscopic colitis, radiation colitis or diverticular disease-associated colitis.
  2. Local manifestations of Crohn's Disease (CD) such as strictures, abscesses, fistula, short bowel syndrome or other disease complications for which surgery might be indicated or could confound the evaluation of efficacy.
  3. Intestinal resection within 6 months or any intra-abdominal surgery within 3 months prior to screening.
  4. Subjects with an ileostomy or a colostomy.
  5. Stool positive for any enteric pathogen or C. difficile toxin at screening.
  6. History of colorectal cancer or colorectal dysplasia.
  7. Prior use of mycophenolic acid, tacrolimus, sirolimus, cyclosporine, thalidomide or apheresis (eg, Adacolumn) for the treatment of CD. In addition, prior use of any of these treatment modalities for an indication other than CD within 8 weeks of screening is also excluded.
  8. Use of intravenous (IV) corticosteroids within 2 weeks of screening.
  9. Use of topical treatment with 5 aminosalicylic acid (5-ASA) or corticosteroid enemas or suppositories within 2 weeks of screening
  10. Use of antibiotic therapy for the treatment of Crohn's Disease (CD) within 3 weeks of screening.
  11. Use of cholestyramine within 3 weeks of screening.
  12. Prior treatment with more than 2 tumor necrosis factor-α (TNF-α) blockers.
  13. Prior treatment with any integrin antagonists (eg, natalizumab or vedolizumab).
  14. Use of tumor necrosis factor-α (TNF-α) blockers within 12 weeks of the screening
  15. Administration of total parenteral nutrition (TPN) within 4 weeks of screening.
  16. History of any clinically significant neurological, renal, hepatic, gastrointestinal, pulmonary, metabolic, cardiovascular, psychiatric, endocrine, hematological disorder or disease, or any other medical condition that, in the Investigator's opinion, would prevent the subject from participation in the study.
  17. Any condition, including the presence of laboratory abnormalities, which places the subject at unacceptable risk if he/she was to participate in the study or confounds the ability to interpret data from the study.
  18. Pregnant or breastfeeding.
  19. History of any of the following cardiac conditions within 6 months of screening: myocardial infarction, acute coronary syndrome, unstable angina, new onset atrial fibrillation, new onset atrial flutter, second- or third-degree atrioventricular block, ventricular fibrillation, ventricular tachycardia, heart failure, cardiac surgery, interventional cardiac catheterization (with or without a stent placement), interventional electrophysiology procedure, or presence of implanted defibrillator.
  20. Known active current or history of recurrent bacterial, viral, fungal, mycobacterial or other infections (including but not limited to tuberculosis and atypical mycobacterial disease and Herpes zoster), human immunodeficiency virus (HIV), or any major episode of infection requiring hospitalization or treatment with intravenous (IV) or oral antibiotics within 4 weeks of screening.
  21. History of congenital or acquired immunodeficiency (eg, common variable immunodeficiency disease).
  22. History of malignancy, except for:

    1. Treated (ie, cured) basal cell or squamous cell in situ skin carcinomas
    2. Treated (ie, cured) cervical intraepithelial neoplasia or carcinoma in situ of the cervix with no evidence of recurrence within the previous 5 years
  23. Subjects who have received any investigational drug or device within 1 months of screening.
  24. Prior treatment with GED-0301, or participation in a clinical study involving GED-0301.
  25. History of alcohol, drug, or chemical abuse within the 6 months prior to screening.
  26. Known hypersensitivity to oligonucleotides or any ingredient in the IP.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT02367183

  Hide Study Locations
Layout table for location information
United States, California
Cedars Sinai Medical Center
Los Angeles, California, United States, 90048
Macks Research Group
Newport Beach, California, United States, 92660
Medical Associates Research Group
San Diego, California, United States, 902123
University of California, San Francisco Medical Center
San Francisco, California, United States, 94115
United States, Florida
Florida Research Network, LLC
Gainesville, Florida, United States, 32605
University of Florida Shands Endoscopy Center University of Florida at Gainesville
Gainesville, Florida, United States, 32608
Borland - Groover Clinic
Jacksonville, Florida, United States, 32256
University of Miami
Miami, Florida, United States, 33136
Gastroenterology Group of Naples
Naples, Florida, United States, 34102
Advanced Medical Research Center
Port Orange, Florida, United States, 32127
Shafran Gastroenterology Center
Winter Park, Florida, United States, 32789
United States, Georgia
Atlanta Gastroenterology Associates, LLC
Atlanta, Georgia, United States, 30342
Gastroenterology Specialists
Suwanee, Georgia, United States, 30024
United States, Kentucky
University of Louisville
Louisville, Kentucky, United States, 40202
United States, Maryland
Metropolitan Gastroenterology
Chevy Chase, Maryland, United States, 20815
United States, Michigan
University of Michigan
Ann Arbor, Michigan, United States, 48109
Clinical Research Institute of Michigan, LLC
Chesterfield, Michigan, United States, 48047
United States, New York
Montefiore Medical Center
Bronx, New York, United States, 10467
NYU Langone Long Island Clinical Research Associates
Great Neck, New York, United States, 11021
Concorde Medical Group
New York, New York, United States, 10016
Cornell University
New York, New York, United States, 10021
Icahn School of Medicine at Mount Sinai
New York, New York, United States, 10029
Rochester General Hospital
Rochester, New York, United States, 14621
United States, North Carolina
Cumberland Research Associates
Fayetteville, North Carolina, United States, 28304
The Management Associates
Wilmington, North Carolina, United States, 28403
United States, Ohio
University Hospitals Case Medical Center
Cleveland, Ohio, United States, 44106
United States, Tennessee
Nashville Gastrointestinal Specialists
Nashville, Tennessee, United States, 37211
United States, Texas
Texas Digestive Disease Consultants - Dallas
Dallas, Texas, United States, 75231
Digestive Disease Consultants
Grapevine, Texas, United States, 76051
Baylor College of Medicine
Houston, Texas, United States, 77030
Texas Digestive Disease Consultants - Southlake
Irving, Texas, United States, 75039
United States, Utah
University of Utah Division of Gastroenterology
Salt Lake City, Utah, United States, 84132
United States, Virginia
McGuire Veterans Affairs Medical Center
Richmond, Virginia, United States, 23249
United States, Washington
University of Washington Medical Center
Seattle, Washington, United States, 98195
Australia, New South Wales
Centre For Digestive Diseases
Five Dock, New South Wales, Australia, 2046
Australia, Queensland
Mater Adult Hospital
South Brisbane, Queensland, Australia, 4101
Australia, South Australia
Royal Adelaide Hospital
Adelaide, South Australia, Australia, 5000
Australia, Victoria
Monash Medical Centre
Clayton, Victoria, Australia, 3168
Concord Repatriation General Hospital
Concord, Australia, 2139
Canada, British Columbia
GI Research Institute
Vancouver, British Columbia, Canada, V6Z 2K5
PerCuro Clinical Research
Victoria, British Columbia, Canada, V8V 3P9
Canada, Ontario
London Health Science Center U. Hospital
London, Ontario, Canada, N6A 5A5
McMaster University Medical Centre
West Hamilton, Ontario, Canada, L8N 3Z5
Szent Imre Korhaz
Budapest, Hungary, 1115
Szegedi Tudomanyegyetem
Szeged, Hungary, 6720
Fakultna nemocnica s poliklinikou F. D. Roosevelta
Banska Bystrica, Slovakia, 975 17
Univerzitna nemocnica Bratislava
Bratislava, Slovakia, 82606
IBD Centrum s.r.o.
Bratislava, Slovakia, 83104
KM Management, spol. s r.o.
Nitra, Slovakia, 949 01
GASTRO I., s.r.o.
Presov, Slovakia, 080 01
Sponsors and Collaborators
Layout table for investigator information
Study Director: Guillermo Rossiter, MD Celgene

Publications automatically indexed to this study by Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Celgene Identifier: NCT02367183     History of Changes
Other Study ID Numbers: GED-0301-CD-001
First Posted: February 20, 2015    Key Record Dates
Last Update Posted: January 10, 2019
Last Verified: January 2019
Keywords provided by Celgene:
Crohn's Disease
Active Crohn's Disease
Additional relevant MeSH terms:
Layout table for MeSH terms
Crohn Disease
Inflammatory Bowel Diseases
Gastrointestinal Diseases
Digestive System Diseases
Intestinal Diseases